Nucleosidi

6-(2-Deoxy-3,5-di-O-toluoyl-b-D-ribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one is a nucleoside analog that inhibits the activity of DNA polymerase and RNA polymerase. It has been shown to be active against human leukemia cells and is currently being used in clinical trials for cancer treatment. 6-(2-Deoxy-3,5-diOtoluoyl b D ribofuranosyl)-3,4 dihydro 8H pyrimido[4,5 c] [1,2]oxazin 7 one is a novel nucleoside analog that has been shown to be effective against both DNA and RNA viruses.

N6-Benzoyl-7'-hydroxy-N-trityl morpholino adenine is a novel Ribonucleoside, which is a synthetic nucleoside with antiviral properties. It has been shown to inhibit the growth of cells in culture by inhibiting the synthesis of DNA and RNA. N6-Benzoyl-7'-hydroxy-N-trityl morpholino adenine has shown cytotoxicity against various cancer cells, including human leukemia cells, human lung cancer cells, and human breast cancer cells. The cytotoxic effects are thought to be due to inhibition of DNA synthesis and RNA synthesis.

P3-(1-(2-Nitrophenyl)ethyl) adenosine 5'-triphosphate disodium salt (P3-ANP-Na2) is an anticancer drug that belongs to the group of nucleosides. It is a phosphoramidate prodrug that is converted to adenosine 5'-triphosphate (ATP) by intracellular esterases. This prodrug has been shown to inhibit the growth of various types of cancer cells in vitro and in vivo, including leukemia and breast cancer cells. P3-ANP-Na2 binds to DNA by intercalation, inhibiting DNA synthesis and transcription. It also inhibits protein synthesis by inhibiting ribonucleotide reductase and deoxyribonucleotide reductase, which are enzymes responsible for synthesizing DNA precursors from RNA precursors.

3'-Azido-3'-deoxy-5-fluorocytidine is an activator with novel antiviral and anticancer properties. It is a high quality, modified nucleoside that can be used to synthesize deoxyribonucleosides and ribonucleosides. 3'-Azido-3'-deoxy-5-fluorocytidine has been shown to inhibit the growth of cancer cells in vitro and in vivo.

TFA-aa-dC is a novel anti-cancer drug that has been shown to have both antiviral and anticancer activities. It is a modified phosphoramidite of 2'-deoxyadenosine 5'-triphosphate with a 3'-amino group (TFA-aa-dC) and an acetyl group at the 2' position. TFA-aa-dC blocks viral replication by inhibiting the activity of viral DNA polymerase, which is required for DNA synthesis. The compound also inhibits cell growth by blocking RNA synthesis and protein production, leading to cell death. TFA-aa-dC has shown efficacy in preclinical studies against cervical cancer and leukemia cells.

1-(2-C-Methyl-b-D-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide is a modified nucleoside that is used as an antiviral and anticancer agent. It is a diphosphate derivative of 1-(2'-deoxyribofuranosyl)-1H-1,2,4-triazole. The compound has been shown to have antiviral activity against herpes simplex virus (HSV) type I and HSV type II in vitro. It also inhibits the growth of human tumor cells in culture by interfering with DNA synthesis. The compound has been reported to be active against leukemia cells in vivo but not against normal cells. It has a high level of toxicity at high doses.

2'-Deoxyguanosine-5'-O-(1-thiotriphosphate) lithium salt is a nucleotide analog that has been shown to inhibit the synthesis of fatty acids and proteins, as well as cause depression in mice. It also has antiviral activity against the type strain of HIV-1 (HXB2). The drug inhibits protein synthesis by preventing the incorporation of amino acids into a growing polypeptide chain. This inhibition can be reversed by adding vitamin D3 or fatty acids. 2'-Deoxyguanosine-5'-O-(1-thiotriphosphate) lithium salt has been shown to have anti-cancer properties due to its ability to induce apoptosis, which is programmed cell death. This drug also has immune functions, such as an increase in natural killer cells and cytokines, as well as improving energy efficiency in the optical system.